Corresponding with reported activity of NF1 as a tumor suppressor and negative regulator of RAS in lung adenocarcinomas [38], truncating mutations in NF1 tend to be mutual exclusive with activating mutations in RAS and BRAF (TCGA) in these tumors (Figure 1A). Here, BRAF is linked to neoplasm.